c-Myc Immunohistochemistry in Diffuse Large B Cell LymphomaGocke, Christopher D. MDPathology Case Reviews: September/October 2014 - Volume 19 - Issue 5 - p 234–238 doi: 10.1097/PCR.0000000000000058 Case Reviews Buy Abstract Author InformationAuthors Article MetricsMetrics Diffuse large B cell lymphoma is a collection of different biologic entities with a common appearance but different clinical behaviors. The MYC oncogene is mutated in a subset of diffuse large B cell lymphoma and is also mutated in related entities such as Burkitt lymphoma. Recently, an antibody to the c-Myc oncoprotein has become available for immunohistochemistry, raising the possibility of a rapid, reproducible and inexpensive measure of MYC abnormality. Initial retrospective studies of these lymphomas suggest that the c-Myc status is clinically important for diagnosis and prognosis, particularly when used in conjunction with BCL2 immunohistochemistry. It is possible that therapy will be modified based in part on c-Myc status, once the appropriate prospective studies have been performed. From the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD. Reprints: Christopher D. Gocke, MD, Associate Professor, Department of Pathology, Johns Hopkins University School of Medicine, 600 N Wolfe St/Park SB202, Baltimore, MD 21287. E-mail: firstname.lastname@example.org. The authors have no funding or conflicts to declare. © 2014 by Lippincott Williams & Wilkins.